These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

248 related items for PubMed ID: 25234311

  • 21. Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience.
    Higashihara E, Torres VE, Chapman AB, Grantham JJ, Bae K, Watnick TJ, Horie S, Nutahara K, Ouyang J, Krasa HB, Czerwiec FS, TEMPOFormula and 156-05-002 Study Investigators.
    Clin J Am Soc Nephrol; 2011 Oct; 6(10):2499-507. PubMed ID: 21903984
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
    Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW, HALT-PKD Study.
    Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
    [Abstract] [Full Text] [Related]

  • 27. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
    Riyahi S, Dev H, Blumenfeld JD, Rennert H, Yin X, Attari H, Barash I, Chicos I, Bobb W, Donahue S, Prince MR.
    J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110
    [Abstract] [Full Text] [Related]

  • 28. Metabolic profiling in children and young adults with autosomal dominant polycystic kidney disease.
    Baliga MM, Klawitter J, Christians U, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Klawitter J.
    Sci Rep; 2021 Mar 23; 11(1):6629. PubMed ID: 33758231
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Podocyte Injury in Autosomal Dominant Polycystic Kidney Disease.
    Cebeci E, Ekinci I, Gursu M, Coskun C, Karadag S, Uzun S, Behlul A, Senel TE, Kazancioglu R, Ozturk S.
    Nephron; 2019 Mar 23; 142(4):311-319. PubMed ID: 31117091
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
    Irazabal MV, Abebe KZ, Bae KT, Perrone RD, Chapman AB, Schrier RW, Yu AS, Braun WE, Steinman TI, Harris PC, Flessner MF, Torres VE, HALT Investigators.
    Nephrol Dial Transplant; 2017 Nov 01; 32(11):1857-1865. PubMed ID: 27484667
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Clinical characteristics associated with 1-year tolvaptan efficacy in autosomal dominant polycystic kidney disease with a wide range of kidney functions.
    Murakami T, Nishimura K, Ono H, Ueta S, Shibata E, Kishi S, Tamaki M, Miya K, Shima H, Tashiro M, Inoue T, Kawahara K, Nagai K, Abe H, Minakuchi J, Doi T.
    J Med Invest; 2020 Nov 01; 67(3.4):315-320. PubMed ID: 33148908
    [Abstract] [Full Text] [Related]

  • 36. Cystatin C estimated glomerular filtration rate to assess renal function in early stages of autosomal dominant polycystic kidney disease.
    Sans L, Radosevic A, Quintian C, Montañés R, Gràcia S, Vilaplana C, Mojal S, Ballarin JA, Fernández-Llama P, Torra R, Pascual J.
    PLoS One; 2017 Nov 01; 12(3):e0174583. PubMed ID: 28346513
    [Abstract] [Full Text] [Related]

  • 37. Predictors of rapid disease progression in autosomal dominant polycystic kidney disease.
    Corradi V, Gastaldon F, Caprara C, Giuliani A, Martino F, Ferrari F, Ronco C.
    Minerva Med; 2017 Feb 01; 108(1):43-56. PubMed ID: 27701376
    [Abstract] [Full Text] [Related]

  • 38. Cisterna chyli in autosomal dominant polycystic kidney disease.
    Thimmappa ND, Blumenfeld JD, Cerilles MA, Dunning A, Donahue SL, Bobb WO, Zhang HL, Prince MR.
    J Magn Reson Imaging; 2015 Jan 01; 41(1):142-8. PubMed ID: 24470398
    [Abstract] [Full Text] [Related]

  • 39. Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.
    Park HC, Kang AY, Jang JY, Kim H, Han M, Oh KH, Kim SH, Noh JW, Cheong HI, Hwang YH, Ahn C.
    BMC Nephrol; 2015 Jun 20; 16():86. PubMed ID: 26092580
    [Abstract] [Full Text] [Related]

  • 40. Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.
    Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, Perrone RD, Steinman TI, Abebe KZ, Rahbari-Oskoui FF, Yu ASL, Harris PC, Bae KT, Hogan M, Miskulin D, Chonchol M.
    J Am Soc Nephrol; 2018 Feb 20; 29(2):571-578. PubMed ID: 29118087
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.